| abstract |
The present invention is a method of treating warm-blooded animals having acute myeloid leukemia (AML) resistant to conventional chemotherapy, wherein the animal has a therapeutically effective amount of Formula I. [Chemical 1] Wherein radicals and symbols have the meanings defined in the specification. ] Or a mixture of compounds, particularly topoisomerase II inhibitors, antimetabolites or antitumor antibiotics, useful for the treatment of AML, for simultaneous, separate or sequential use, together or in combination And a pharmaceutical composition and product packaging comprising the combination. |